Results 11 to 20 of about 16,055,883 (292)

Development of a Biphasic Modified-Release Ibuprofen Tablet Formulation: Single-Dose and Multiple-Dose Pharmacokinetics and Food-Effect Studies. [PDF]

open access: yesClin Transl Sci
Ibuprofen is the most commonly used NSAID; however, its short biological half‐life, reflected in the short duration of pain relief, limits the comfortableness of its usage. This study evaluated the pharmacokinetic properties of a newly developed biphasic
Kvapilová L   +6 more
europepmc   +2 more sources

A randomized, open-label, two-period crossover study to evaluate the bioequivalence and food effect between two formulations of regorafenib in healthy adult participants. [PDF]

open access: yesFront Pharmacol
BackgroundThis research aimed to compare the bioequivalence of a test formulation (regorafenib produced by Beijing SL Pharmaceutical Co., Ltd.) with a reference formulation (the original drug Stivarga®) in Chinese healthy subjects under fasting ...
Li Y, Qi L, Yang C, Zhao N, Wang X.
europepmc   +2 more sources

Consideration on Food Effect Studies for Anticancer Drugs Approved in Japan Between 2001 and 2022. [PDF]

open access: yesClin Transl Sci
In developing a new drug, studies to evaluate the food effect (FE) on the drug's pharmacokinetics (FE studies) are generally conducted in healthy subjects in the early stages of clinical development.
Shibuya M, Kubota H, Maeda H.
europepmc   +2 more sources

Food Effect and Formulation: How Soluble Fillers Affect the Disintegration and Dissolution of Tablets in Viscous Simulated Fed State Media. [PDF]

open access: yesPharmaceutics
The food-induced viscosity of the media can alter tablet disintegration and eventually the release of the drug it contains. The extent of this retardation depends on tablet formulation factors, such as the solubility of its excipients.
Umer MF   +8 more
europepmc   +2 more sources

Diets, Foods and Food Components’ Effect on Dyslipidemia [PDF]

open access: yesNutrients, 2021
Hypercholesterolemia is a well-known independent risk factor for cardiovascular disease and a recognized target of pharmacological therapeutic agents in both primary and secondary prevention [...]
Federica Fogacci   +2 more
openaire   +2 more sources

Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study

open access: yesAnnals of Medicine, 2023
Background: TQA3526 is a novel farnesoid X receptor agonist developed to treat non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC).
Jia Xu   +9 more
doaj   +1 more source

High-fat diets enhance and delay ursodeoxycholic acid absorption but elevate circulating hydrophobic bile salts

open access: yesFrontiers in Pharmacology, 2023
Background: Ursodeoxycholic acid (UDCA) is a natural drug essential for the treatment of cholestatic liver diseases. The food effects on the absorption of UDCA and the disposition of circulating bile salts remain unclear despite its widespread global ...
Liang Huang   +15 more
doaj   +1 more source

Pharmacokinetic characteristics of golidocitinib, a highly selective JAK1 inhibitor, in healthy adult participants

open access: yesFrontiers in Immunology, 2023
BackgroundGolidocitinib is an orally available, potent and highly selective JAK (Janus kinase)-1 inhibitor of JAK/STAT3 signaling under clinical development for the treatment of cancer and autoimmune diseases.
Kan Chen   +11 more
doaj   +1 more source

Bioequivalence and food effect of a fixed‐dose combination of macitentan and tadalafil: Adaptive design in the COVID‐19 pandemic

open access: yesPharmacology Research & Perspectives, 2021
The COVID‐19 pandemic has forced clinical studies to accommodate imposed limitations. In this study, the bioequivalence part could not be conducted as planned.
Dénes Csonka   +6 more
doaj   +1 more source

Effect of a high‐fat and high‐calorie food on the pharmacokinetics of a novel, potent GABA analog HSK16149 in healthy subjects

open access: yesPharmacology Research & Perspectives, 2023
HSK16149 is a novel, potent gamma‐aminobutyric acid (GABA) analog for the treatment of neuropathic pain. The purpose of this study was to assess the effect of a high‐fat and high‐calorie meal on the pharmacokinetics of HSK16149 in healthy Chinese ...
Qingqing Wu   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy